基于新靶点的抗糖尿病药物研究进展

随着研究者对糖尿病发病机制研究的不断深入，许多治疗糖尿病的新靶点不断被发现和报道，多种抗糖尿病新药(如利格列汀、艾塞那肽、达格列净等)陆续上市，有多个针对不同靶点的新药处于临床后期研究阶段，这些进展将为糖尿病的治疗提供新的手段。G蛋白偶联受体119(GPR119)、G蛋白偶联受体40(GPR40)、G蛋白偶联受体120(GPR120)、单磷酸腺苷活化蛋白激酶(AMPK)、Apelin受体以及糖原合成酶激酶3β(GSK3β)是几类在当前和未来具有研究价值和开发潜力的抗糖尿病药物新靶点。本文总结了这些靶点的作用途径，并对基于这些新靶点的药物及其研发现状进行了综述。
With the deepening of research, different new anti-diabetic drug targets have been discovered and reported, several categories of anti-diabetic drugs(linagliptin, exenatide, dapagliflozin, etc. )have been brought to the market and some new drugs acting on different targets are in late-stage clinical trials. All these progresses provide new means for overcoming diabetes. GPR119, GPR120, GPR40, AMPK, apelin receptor and GSK3β are anti-diabetic targets with great research values in current days and the future. This article reviews the mechanisms, drugs and research advances with respect to the above-mentioned targets